Department of Pharmacology and Therapeutics, Faculty of Pharmacy, Beirut Arab University, P.O. Box 11-5020, Beirut, Lebanon.
Department of Pharmacology and Toxicology, Faculty of Pharmacy, Alexandria University, Alexandria, Egypt.
Curr Pharm Des. 2021;27(18):2099-2111. doi: 10.2174/1381612827666210122142811.
Atherosclerosis-related cardiovascular diseases (CVDs) are the leading cause of death globally. Several lines of evidence are supportive of the contributory role of vascular inflammation in atherosclerosis. Diverse immune cell types, including monocytes/macrophages, T-cells and neutrophils, as well as specialized proresolving lipid mediators, have been successfully characterized as key players in vascular inflammation. The increased prevalence of atherosclerotic CVD in men in comparison to age-matched premenopausal women and the abolition of sex differences in prevalence during menopause strongly suggest a pivotal role of sex hormones in the development of CVD. Indeed, many animal and human studies conclusively implicate sex hormones as a crucial component in driving the immune response. This is further corroborated by the effective identification of sex hormone receptors in vascular endothelial cells, vascular smooth muscle cells and immune cells. Collectively, these findings suggest a cellular communication between sex hormones and vascular or immune cells underlying the vascular inflammation in atherosclerosis. The aim of this review is to provide an overview of vascular inflammation as a causal cue underlying atherosclerotic CVDs within the context of the modulatory effects of sex hormones. Moreover, the cellular and molecular signaling pathways underlying the sex hormones- immune system interactions as potential culprits for vascular inflammation are highlighted with detailed and critical discussion. Finally, the review concludes by speculations on the potential sex-related efficacy of currently available immunotherapies in mitigating vascular inflammation. Conceivably, a deeper understanding of the immunoregulatory influence of sex hormones on vascular inflammation-mediated atherosclerosis permits sex-based management of atherosclerosis-related CVDs.
动脉粥样硬化相关的心血管疾病(CVDs)是全球范围内的主要死亡原因。有几条证据支持血管炎症在动脉粥样硬化中的促成作用。多种免疫细胞类型,包括单核细胞/巨噬细胞、T 细胞和中性粒细胞,以及专门的促解决脂质介质,已被成功地描述为血管炎症的关键参与者。与年龄匹配的绝经前女性相比,男性动脉粥样硬化性 CVD 的患病率增加,以及绝经后患病率的性别差异消失,这强烈表明性激素在 CVD 的发展中起着关键作用。事实上,许多动物和人类研究都明确表明性激素是驱动免疫反应的关键因素。这进一步得到了在血管内皮细胞、血管平滑肌细胞和免疫细胞中鉴定出性激素受体的证实。综上所述,这些发现表明性激素与血管或免疫细胞之间存在细胞通讯,这是动脉粥样硬化中血管炎症的基础。本综述的目的是提供一个概述,即在性激素调节作用的背景下,将血管炎症作为动脉粥样硬化性 CVD 的因果线索。此外,还详细讨论了性激素-免疫系统相互作用的细胞和分子信号通路,这些通路可能是血管炎症的罪魁祸首。最后,通过推测目前可用的免疫疗法在减轻血管炎症方面的潜在性别疗效,本文进行了总结。可以想象,深入了解性激素对血管炎症介导的动脉粥样硬化的免疫调节影响,可以实现基于性别的动脉粥样硬化相关 CVD 的管理。